Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. The company is headquartered in La Jolla, California. The firm develops products that facilitate the early detection of skin cancers, assess inflammatory diseases and customize drug treatments. The firm provides Adhesive Skin Collection Kit, which is designed to collect stratum corneum tissues of the skin from all locations of the body, with the exception of mucosals surfaces, palmar and plantar surfaces, and areas with excessive non-vellus hair. The company provides Pigmented Lesion Assay (PLA), which assesses pigmented skin lesions, moles or dark skin spots for melanoma. The company offers Nevome, which is the test to non-invasively identify pigmented lesions by analyzing known deoxyribonucleic acid (DNA) mutation risk factors for melanoma. The firm is also engaged in developing gene expression assays to identify cytokine inflammatory profiles that assist clinicians in guiding therapy. The company also offers ResponseTNF product and CytokineEx 17 product.
Website: dermtech.com



Growth: Good revenue growth rate 33.3%, there is slowdown compared to average historical growth rates 52.1%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of +74.2%

Profitability: LTM EBITDA margin is negative, -680.0%. On average the margin is decreasing steadily. Gross margin is low, +11.2%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -319.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 7.4% higher than minimum and 98.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -29.2x by EV / Sales multiple

Key Financials (Download financials)

Ticker: DMTK
Share price, USD:  (-0.1%)0.629
year average price 1.7288  


year start price 2.3100 2023-05-06

max close price 3.7900 2023-07-19

min close price 0.5854 2024-04-25

current price 0.6290 2024-05-04
Common stocks: 34 326 638

Dividend Yield:  0.0%
Last revenue growth (y/y):  33.3%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  52.1%
Historical growth of EBITDA:  0.0%
EV / Sales: 1.4x
Margin (EBITDA LTM / Revenue): -680.0%
Fundamental value created in LTM:
Market Cap ($m): 22
Net Debt ($m): -1
EV (Enterprise Value): 21
Price to Book: 0.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-02-29Zacks Investment Research

DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates

2023-08-03Seeking Alpha

DermTech, Inc. (DMTK) Q2 2023 Earnings Call Transcript

2023-06-20The Motley Fool

If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position

2023-05-04Zacks Investment Research

DermTech, Inc. (DMTK) Reports Q1 Loss, Lags Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DMTK DMTK DMTK DMTK DMTK DMTK
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-29 2023-11-02 2023-08-03 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-02-29 16:53:38 2023-11-02 16:31:47 2023-08-03 16:37:29 2023-05-04 16:33:38 2023-03-02 16:36:39 2022-11-03 16:46:57
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 4M 4M 4M 3M 3M 4M
costOfRevenue 3M 4M 4M 4M 3M 4M
grossProfit 440 000 172 000 8000.000 -344 000 -356 000 -121 000
grossProfitRatio 0.112 0.044 0.002 -0.099 -0.119 -0.034
researchAndDevelopmentExpenses 3M 4M 4M 4M 5M 6M
generalAndAdministrativeExpenses 8M 8M 15M 12M 10M 9M
sellingAndMarketingExpenses 8M 8M 13M 15M 14M 15M
sellingGeneralAndAdministrativeExpenses 17M 16M 28M 27M 23M 23M
otherExpenses 0 0 0 0 0 0
operatingExpenses 20M 20M 32M 32M 29M 29M
costAndExpenses 24M 24M 36M 36M 32M 33M
interestIncome 660 000 641 000 763 000 782 000 641 000 485 000
interestExpense 775 000 0 0 -775 000 641 000 485 000
depreciationAndAmortization 1M 1M 1M 7000.000 -15 000 1M
ebitda -18M -18M -31M -32M -29M -28M
ebitdaratio -4.691 -4.717 -7.703 -9.214 -9.651 -7.883
operatingIncome -20M -20M -32M -32M -29M -29M
operatingIncomeRatio -5.034 -5.060 -8.073 -9.216 -9.646 -8.189
totalOtherIncomeExpensesNet 661 000 5000.000 6000.000 775 000 656 000 489 000
incomeBeforeTax -19M -19M -31M -31M -28M -29M
incomeBeforeTaxRatio -4.865 -4.895 -7.880 -8.993 -9.427 -8.053
incomeTaxExpense 2M -646 000 -769 000 -775 000 -1M -978 000
netIncome -19M -19M -31M -30M -27M -28M
netIncomeRatio -4.865 -4.895 -7.880 -8.770 -8.988 -7.779
eps -0.560 -0.570 -0.990 -1.000 -0.890 -0.920
epsdiluted -0.560 -0.570 -0.990 -1.000 -0.890 -0.920
weightedAverageShsOut 34M 34M 32M 31M 30M 30M
weightedAverageShsOutDil 34M 34M 32M 31M 30M 30M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DMTK DMTK DMTK DMTK DMTK DMTK
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-29 2023-11-02 2023-08-03 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-02-29 16:53:38 2023-11-02 16:31:47 2023-08-03 16:37:29 2023-05-04 16:33:38 2023-03-02 16:36:39 2022-11-03 16:46:57
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 37M 37M 43M 48M 78M 95M
shortTermInvestments 19M 31M 43M 56M 48M 54M
cashAndShortTermInvestments 56M 68M 86M 105M 126M 149M
netReceivables 3M 4M 4M 4M 4M 6M
inventory 1M 1M 1M 2M 2M 1M
otherCurrentAssets 2M 530 000 816 000 2M 4M 643 000
totalCurrentAssets 62M 76M 94M 112M 136M 161M
propertyPlantEquipmentNet 57M 59M 60M 61M 62M 30M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 3M 3M 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 0 0 3M 4M 4M 4M
totalNonCurrentAssets 60M 62M 63M 65M 66M 33M
otherAssets 0 0 0 0 0 0
totalAssets 122M 138M 157M 177M 202M 194M
accountPayables 1M 2M 2M 2M 2M 3M
shortTermDebt 3M 3M 2M 2M 2M 2M
taxPayables 0 0 0 0 0 0
deferredRevenue 196 000 236 000 295 000 242 000 109 000 417 000
otherCurrentLiabilities 9M 8M 11M 12M 11M 12M
totalCurrentLiabilities 13M 13M 16M 16M 16M 17M
longTermDebt 51M 52M 53M 54M 54M 22M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities -1.000 1000.000 6000.000 12 000 5000.000 17M
totalNonCurrentLiabilities 51M 52M 53M 54M 54M 22M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 51M 55M 55M 56M 56M 24M
totalLiabilities 65M 65M 69M 70M 70M 39M
preferredStock 0 0 0 0 0 0
commonStock 3000.000 3000.000 3000.000 3000.000 3000.000 3000.000
retainedEarnings -424M -405M -386M -354M -323M -295M
accumulatedOtherComprehensiveIncomeLoss 178 000 127 000 -101 000 -289 000 -774 000 -1M
othertotalStockholdersEquity 481M 478M 474M 462M 456M 451M
totalStockholdersEquity 57M 73M 88M 107M 132M 155M
totalEquity 57M 73M 88M 107M 132M 155M
totalLiabilitiesAndStockholdersEquity 122M 138M 157M 177M 202M 194M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 122M 138M 157M 177M 202M 194M
totalInvestments 23M 31M 43M 56M 48M 54M
totalDebt 54M 55M 55M 56M 56M 24M
netDebt 18M 18M 13M 7M -22M -72M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol DMTK DMTK DMTK DMTK DMTK DMTK
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-29 2023-11-02 2023-08-03 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-02-29 16:53:38 2023-11-02 16:31:47 2023-08-03 16:37:29 2023-05-04 16:33:38 2023-03-02 16:36:39 2022-11-03 16:46:57
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -19M -19M -31M -31M -28M -29M
depreciationAndAmortization 1M 1M 1M 2M 1M 1M
deferredIncomeTax -5M 0 7M 0 0 0
stockBasedCompensation 3M 3M 8M 5M 5M 5M
changeInWorkingCapital 2M -4M -672 000 3M 208 000 -2M
accountsReceivables 1M 260 000 -175 000 482 000 2M -139 000
inventory 192 000 156 000 222 000 183 000 -366 000 41 000
accountsPayables -174 000 -3M -479 000 1M 2M 0
otherWorkingCapital 1M -2M -240 000 1M -3M -2M
otherNonCashItems 5M -146 000 -8M -28 000 33 000 106 000
netCashProvidedByOperatingActivities -13M -19M -23M -22M -21M -25M
investmentsInPropertyPlantAndEquipment 163 000 -49 000 -259 000 -757 000 -2M -12 000
acquisitionsNet -12M -13M 0 485 000 -650 000 0
purchasesOfInvestments -20 000 -9M -9M -16M -5M -6M
salesMaturitiesOfInvestments 12M 22M 22M 9M 11M 6M
otherInvestingActivites 12M 13M 0 -485 000 650 000 0
netCashUsedForInvestingActivites 12M 13M 13M -8M 4M -466 000
debtRepayment -24 000 -34 000 -34 000 -22 000 -33 000 -44 000
commonStockIssued 0 483 000 4M 270 000 22 000 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 277 000 0 668 000 -22 000 477 000
netCashUsedProvidedByFinancingActivities -24 000 726 000 4M 916 000 -33 000 433 000
effectOfForexChangesOnCash -1000.000 0 13M 0 0 0
netChangeInCash -489 000 -6M -6M -29M -18M -25M
cashAtEndOfPeriod 37M 41M 46M 52M 81M 99M
cashAtBeginningOfPeriod 37M 46M 52M 81M 99M 124M
operatingCashFlow -13M -19M -23M -22M -21M -25M
capitalExpenditure 163 000 -49 000 -259 000 -757 000 -2M -12 000
freeCashFlow -13M -19M -23M -23M -23M -25M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-03-02 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-18 20:15 ET
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan
2024-04-01 20:05 ET
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-08 13:05 ET
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology
2024-02-29 21:01 ET
DermTech Reports Fourth-Quarter 2023 Financial Results
2024-02-13 13:05 ET
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results
2024-01-31 21:30 ET
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
2024-01-18 13:05 ET
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types
2024-01-16 13:05 ET
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay
2024-01-08 13:00 ET
DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)
2023-12-14 21:05 ET
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-02 20:01 ET
DermTech Reports Third-Quarter 2023 Financial Results
2023-10-12 12:05 ET
DermTech Announces Release Date for Third-Quarter 2023 Financial Results
2023-09-21 20:05 ET
DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
2023-09-19 12:05 ET
DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)
2023-09-11 12:05 ET
DermTech Appoints Mark Aguillard as Chief Commercial Officer
2023-08-25 12:05 ET
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-03 20:01 ET
DermTech Reports Second-Quarter 2023 Financial Results
2023-07-19 12:00 ET
DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
2023-07-17 12:00 ET
DermTech Announces Release Date for Second-Quarter 2023 Financial Results
2023-07-12 12:00 ET
DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
2023-06-28 20:30 ET
DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations
2023-06-14 12:00 ET
ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)
2023-06-07 12:00 ET
DermTech Announces Contract With Hawaii Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
2023-06-02 20:05 ET
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-05-31 12:00 ET
DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT)
2023-05-11 12:00 ET
DermTech Announces Agreements With South Carolina Blues Plan and the United Mine Workers of America Health and Retirement Funds for the Foundational Assay of Its DermTech Melanoma Test (DMT)
2023-05-10 13:37 ET
Regular Skin Checks Are the Key to Melanoma Detection
2023-05-10 12:00 ET
DermTech Grants New CEO Bret Christensen Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
2023-05-09 12:00 ET
DermTech Appoints Bret Christensen as New President and CEO
2023-05-04 20:01 ET
DermTech Reports First-Quarter 2023 Financial Results
2023-05-01 20:30 ET
New Survey Data Reveals Nearly 75% of Consumers Have Not Had a Full Skin Exam Within the Past 12 Months
2023-04-26 12:05 ET
DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
2023-04-13 12:05 ET
DermTech Announces Release Date for First-quarter 2023 Financial Results
2023-04-11 12:05 ET
DermTech Announces Contract With North Carolina Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
2023-04-05 14:00 ET
New Survey Finds Millennials and Gen Xers Not Following Safe Sun Habits, Increasing Risk of Nonmelanoma Skin Cancer
2023-04-03 20:15 ET
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-14 20:30 ET
DermTech to Present Four New Posters and Demonstrate its Smart Stickers™ at the 2023 American Academy of Dermatology (AAD) Annual Meeting
2023-03-07 13:05 ET
DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
2023-03-03 13:05 ET
DermTech to Present at March Investor Conferences
2023-03-02 21:01 ET
DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan
2023-02-10 13:30 ET
DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results
2023-02-09 13:30 ET
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration
2023-01-27 13:30 ET
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2023-01-23 13:30 ET
DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
2023-01-10 13:30 ET
DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE
2023-01-05 13:30 ET
DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)
2022-12-16 21:05 ET
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-15 21:30 ET
DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test
2022-11-03 20:01 ET
DermTech Reports Third-Quarter 2022 Financial Results
2022-10-13 20:05 ET
DermTech Announces Release Date for Third-Quarter 2022 Financial Results
2022-10-10 20:30 ET
DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress
2022-10-10 20:05 ET
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-10-03 20:30 ET
DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern California
2022-09-16 20:30 ET
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-08 20:01 ET
DermTech Reports Second-Quarter 2022 Financial Results; Company Updates Full-Year 2022 Outlook
2022-07-28 20:05 ET
DermTech Appoints Chief Compliance Officer and SVP of Research and Development
2022-07-26 20:05 ET
DermTech Announces Release Date for Second-Quarter 2022 Financial Results
2022-07-18 20:05 ET
DermTech Appoints Two New Board Members
2022-07-06 20:30 ET
DermTech Joins PeDRA Corporate Council, Supporting Efforts to Address Pediatric Skin Diseases
2022-06-14 20:05 ET
DermTech to Present on Genomic Innovation in Dermatology at AHIP 2022
2022-06-07 21:00 ET
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-01 20:05 ET
DermTech to Present at the William Blair Growth Stock Conference
2022-05-24 20:30 ET
DermTech Sponsors The Sun Bus to Bring Free Skin Cancer Screenings to More Than 50 Locations Across the U.S.
2022-05-18 20:30 ET
DermTech Presents New Research Differentiating Atopic Dermatitis and Psoriasis at the Society for Investigative Dermatology’s Annual Meeting
2022-05-10 20:30 ET
DermTech Reinforces Longstanding Mission to Help Reduce Melanoma Deaths, Aligning with the Biden Administration’s Renewed ‘Cancer Moonshot’ Program
2022-05-04 20:30 ET
DermTech Kicks Off Second Annual #Stickit2Melanoma Campaign, Raising Awareness for Melanoma and the Importance of Skin Exams
2022-05-03 20:05 ET
DermTech Reports First-Quarter 2022 Financial Results; Company Affirms Full-Year 2022 Outlook
2022-04-28 20:30 ET
DermTech Announces Publication of New GvHD Clinical Research Conducted in Collaboration with Memorial Sloan Kettering Cancer Center
2022-04-26 20:30 ET
DermTech Expands Telehealth Application, DermTech Connect, Across 44 States
2022-04-25 20:30 ET
DermTech to Showcase DermTech Stratum, an Expanded Translational Medicine Service Offering, at San Diego’s Inaugural ‘Innovation Day’ Event
2022-04-14 20:01 ET
DermTech Announces Release Date for First-Quarter 2022 Financial Results
2022-03-28 20:01 ET
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-08 14:00 ET
DermTech Study, “Cost-Benefit Analysis of the Pigmented Lesion Assay When Introduced into the Visual Assessment / Histopathology Pathway for Lesions Clinically Suspicious for Melanoma,” Published in SKIN: The Journal of Cutaneous Medicine
2022-03-01 21:01 ET
DermTech Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-24 21:01 ET
DermTech Management to Present at Upcoming Investor Conferences
2022-02-23 21:30 ET
DermTech Welcomes Adelle Walker as Vice President of Consumer Products
2022-02-15 21:01 ET
DermTech to Announce Fourth Quarter and Full-Year Financial Results
2022-01-31 21:01 ET
DermTech Management to Participate in Upcoming Investor Conferences
2021-12-15 17:23 ET
BioIQ and DermTech Enter into an Agreement to Add Non-invasive DermTech Melanoma Test to BioIQ's Health Testing Solution Lineup
2021-11-29 21:30 ET
DermTech Unveils DermTech Stratum, an Expanded Translational Medicine Service Offering for Non-invasive Biomarker Analysis
2021-11-18 21:30 ET
DermTech Presents Precision Approaches to Personalized Dermatology at 2021 Dermatology Drug Development Summit
2021-11-09 21:01 ET
DermTech Reports Third Quarter 2021 Financial Results
2021-11-08 21:50 ET
DermTech and DermatologistOnCall Enter Agreement to Improve Access to the DermTech Melanoma Test with Noninvasive, At-Home Sample Collection
2021-11-02 20:01 ET
DermTech Management to Participate in Upcoming Investor Conferences
2021-10-26 20:01 ET
DermTech to Announce Third Quarter Financial Results on November 9, 2021
2021-10-11 20:30 ET
DermTech Presents in Expert Panel at Inaugural Alliance for Innovation in Integrated Healthcare Summit
2021-10-04 20:01 ET
DermTech Announces New Appointment of L’Oréal USA Leader Nathalie Gerschtein Keraudy to its Board of Directors
2021-09-27 20:30 ET
DermTech Sponsors San Diego Open; Partners with Tennis Pro Brandon Nakashima to Raise Awareness for Sun Safety
2021-09-14 11:00 ET
DermTech Study, “Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden,” Published in SKIN: The Journal Of Cutaneous Medicine
2021-09-08 20:01 ET
DermTech Management to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
2021-09-02 20:30 ET
DermTech to Present at Florida Association of Health Plans 2021 Annual Conference
2021-08-31 20:01 ET
DermTech Management to Participate at the Lake Street 2021 BIG5 Conference
2021-08-04 20:01 ET
DermTech Reports Second Quarter 2021 Financial Results
2021-07-21 20:30 ET
DermTech to Announce Second Quarter Financial Results on August 4, 2021
2021-07-21 20:05 ET
DermTech Announces New San Diego Headquarters
2021-07-06 12:00 ET
DermTech Announces New Appointment of Monica Tellado to its Board of Directors
2021-06-24 21:00 ET
DermTech CEO John Dobak, M.D. Wins San Diego Business Journal CEO of the Year Award, Public Company, Medium Category
2021-06-22 20:30 ET
DermTech to Partner with University of Barcelona for Research Study on Atopic Dermatitis and Psoriasis
2021-06-16 20:01 ET
DermTech Announces Three New Key Leadership Appointments: Chief Medical Officer, Vice President, Sales and Vice President, Information Technology and Digital Systems
2021-06-02 20:30 ET
DermTech Announces Three New Scientific Advisory Board Members
2021-05-24 13:00 ET
DermTech Helps Detect Skin Cancer Through a Smart Sticker Instead of a Scalpel
2021-05-18 20:01 ET
DermTech Management to Participate in Upcoming Investor Conferences
2021-05-13 20:01 ET
DermTech Reports First Quarter 2021 Financial Results
2021-05-11 20:01 ET
DermTech Management to Present at the UBS Global Healthcare Virtual Conference
2021-05-10 20:30 ET
DermTech Presents Mini-Symposia at 2021 Society of Investigational Dermatology Virtual Summit
2021-05-03 20:30 ET
DermTech Pledges up to $1 Million to Raise Awareness and Support Accessibility of Skin Exams
2021-04-29 20:01 ET
DermTech to Announce First Quarter Financial Results on May 13, 2021
2021-04-27 20:30 ET
DermTech to Collaborate on Longitudinal Study on Hidradenitis Suppurativa (HS)
2021-04-22 20:30 ET
DermTech Introduces PLAplus with Improved Sensitivity for Early Detection of Melanoma
2021-04-19 20:30 ET
DermTech Joins Skin Cancer Foundation Corporate Council
2021-04-15 20:01 ET
OptumInsight Study Describes Cost Savings of DermTech’s Pigmented Lesion Assay in the Management of Melanoma
2021-03-04 21:01 ET
DermTech Reports Fourth Quarter and Full Year 2020 Financial Results
2021-02-22 21:30 ET
DermTech Abstracts Selected to Present at Society of Investigative Dermatology Virtual Meeting
2021-02-18 21:01 ET
DermTech to Announce Fourth Quarter 2020 Financial Results on March 4, 2021
2021-02-17 21:01 ET
DermTech Management to Participate in Upcoming Investor Conferences
2021-02-10 21:01 ET
DermTech Enters Into Agreement with Blue Cross Blue Shield of Texas
2021-02-08 21:30 ET
DermTech Announces New Scientific Advisory Board Members
2021-02-03 21:01 ET
DermTech Management to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
2021-01-28 21:30 ET
DermTech Featured in Melanoma Research Foundation Weekly “Ask the Expert” Facebook Live Events Alongside Notable Industry Scientists
2021-01-19 21:30 ET
DermTech Chief Scientific Officer Michael Howell Presented at Dermatology Summit 2021
2021-01-14 21:30 ET
DermTech Pigmented Lesion Assay (PLA) to Enrich Melanoma Positivity Nearly Five-Fold in Biopsied Lesions: Findings from a Large US Registry
2021-01-12 21:01 ET
DermTech Announces Inclusion of Non-Invasive Genomic Patch Testing in the National Comprehensive Cancer Network® (NCCN) Cutaneous Melanoma Guidelines
2021-01-11 21:01 ET
DermTech Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-01-07 05:00 ET
DermTech Announces Pricing of Public Offering of Common Stock
2021-01-06 21:01 ET
DermTech Announces Proposed Public Offering of Common Stock
2021-01-05 21:30 ET
DermTech Announces Appointment of General Counsel
2020-12-29 22:05 ET
DermTech Receives Positive Medical Coverage by Geisinger Health System
2020-12-28 21:01 ET
DermTech Management to Present at the ICR Conference 2021
2020-12-17 21:30 ET
DermTech Announces Topline Results of its TRUST Study: Results Confirm the High Negative Predictive Value of the PLA at 99% and Find No Significant Adverse Outcomes After Long-Term Follow-Up of PLA Negative Tests
2020-12-11 14:00 ET
DermTech’s Melanoma Test Included in Two Continuing Medical Education (“CME”) Sessions at 2020 Fall Clinical Virtual Grand Rounds and Mount Sinai Winter Symposium
2020-12-10 21:01 ET
DermTech Enters Into Agreement With Blue Shield of California
2020-12-03 21:30 ET
DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit
2020-11-20 13:00 ET
DermTech Enters Agreement with Blue Cross Blue Shield of Illinois
2020-11-17 21:30 ET
DermTech Presents New Clinical Research Abstract at the 2020 Fall Clinical Dermatology Conference
2020-11-10 21:01 ET
DermTech Reports Third Quarter 2020 Financial Results
2020-11-04 21:01 ET
DermTech to Participate in Upcoming Investor Conferences
2020-10-27 20:01 ET
DermTech to Announce Third Quarter 2020 Financial Results on November 10, 2020
2020-09-08 12:00 ET
DermTech Announces Appointment of Chief Scientific Officer
2020-09-03 20:01 ET
DermTech to Participate in Upcoming Investor Conferences
2020-08-05 20:01 ET
DermTech, Inc. Reports Second Quarter 2020 Financial Results and Provides Corporate Update
2020-06-30 12:00 ET
DermTech Announces Inclusion in the Russell 2000 Index
2020-05-20 20:30 ET
DermTech PLA Included in Peer Review Article of Novel Molecular Technologies for Melanoma Management with Potential to Address Current Gaps in Diagnostic Accuracy and Prognostication
2020-05-13 20:01 ET
DermTech, Inc. Reports First Quarter 2020 Financial Results and Provides Corporate Update
2020-05-11 21:00 ET
Proof-of-Concept Research Demonstrates Patients Reliably Perform Remote Self-Sampling of Concerning Moles Using DermTech’s Non-Invasive Adhesive Skin Collection Kit Under Physician Supervision via Telemedicine
2020-05-05 13:15 ET
 The Melanoma Research Foundation Hosting Weekly Facebook Live ‘Ask a Dermatologist’ Sessions throughout Melanoma Awareness Month
2020-04-30 20:41 ET
DermTech Announces Telemedicine Solution to Enable Remote Use of its Non-Invasive Adhesive Patch Test for Melanoma Detection
2020-03-25 12:00 ET
DermTech Announces Response to COVID-19
2020-03-16 13:33 ET
New Study Shows Combining TERT Mutation Analyses With DermTech’s PLA Provides Improved Sensitivity for Detecting Melanoma With Non-invasive Patches
2020-03-10 20:01 ET
DermTech, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
2020-03-05 13:00 ET
Large Registry Study Demonstrates Clinicians Use DermTech’s Non-Invasive Gene Expression Testing to Improve Early Melanoma Detection
2020-03-03 21:05 ET
DermTech to Participate at the 2020 BTIG Healthcare Conference
2020-03-02 11:00 ET
 DermTech Announces $65 Million Private Placement
2020-02-11 22:29 ET
DermTech to Present at Upcoming Investor Conferences
2020-01-16 22:45 ET
DermTech Enters into Commercial and Medicare Advantage Payor Coverage Contract for the Pigmented Lesion Assay
2020-01-08 13:00 ET
CMS Releases Final 2020 Clinical Lab Fee Schedule (CLFS) Including Pricing for DermTech’s Pigmented Lesion Assay (PLA)
2020-01-02 13:00 ET
DermTech’s Pigmented Lesion Assay (PLA) Receives Medicare Coverage
2019-11-07 18:30 ET
DermTech, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update
2019-11-06 19:28 ET
DermTech to Present at Upcoming Investor Conferences
2019-10-28 12:00 ET
DermTech Receives CPT® Proprietary Laboratory Assay Code from the American Medical Association
2019-10-22 12:00 ET
DermTech Presents New Data at Fall Clinical Dermatology Conference
2019-10-18 20:15 ET
DermTech Announces Common Stock Will Continue Trading on The Nasdaq Capital Market; Warrant Delisting from The Nasdaq Capital Market
2019-10-15 12:00 ET
DermTech’s Test Included in Expert Panel’s Clinical Management Recommendations for Cutaneous Melanoma
2019-10-07 12:00 ET
DermTech Further Expands Patent Portfolio
2019-09-16 20:30 ET
DermTech Announces Appointment of Kevin Sun as Chief Financial Officer
2019-05-29 20:30 ET
Constellation Alpha Capital Corp. to Merge with DermTech, Inc., a leading innovator of genomics for dermatology and non-invasive skin cancer diagnosis

SEC forms

Show financial reports only

SEC form 10
2024-02-29 16:53 ET
DermTech published news for 2023 q4
SEC form 8
2024-02-29 16:05 ET
DermTech published news for 2023 q4
SEC form 8
2024-02-29 16:05 ET
DermTech reported for 2023 q4
SEC form 10
2024-02-29 00:00 ET
DermTech published news for 2023 q4
SEC form 10
2023-11-02 16:31 ET
DermTech published news for 2023 q3
SEC form 8
2023-11-02 16:09 ET
DermTech reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
DermTech published news for 2023 q3
SEC form 10
2023-08-03 16:37 ET
DermTech reported for 2023 q2
SEC form 6
2023-08-03 16:07 ET
DermTech published news for 2023 q2
SEC form 10
2023-08-03 00:00 ET
DermTech published news for 2023 q2
SEC form 8
2023-08-03 00:00 ET
DermTech published news for 2023 q2
SEC form 6
2023-07-13 16:09 ET
DermTech published news for 2023 q2
SEC form 6
2023-06-28 16:35 ET
DermTech published news for 2023 q1
SEC form 6
2023-06-05 18:45 ET
DermTech published news for 2023 q1
SEC form 6
2023-06-05 18:39 ET
DermTech published news for 2023 q1
SEC form 6
2023-06-05 18:30 ET
DermTech published news for 2023 q1
SEC form 6
2023-06-05 18:27 ET
DermTech published news for 2023 q1
SEC form 6
2023-06-05 18:22 ET
DermTech published news for 2023 q1
SEC form 6
2023-06-05 18:20 ET
DermTech published news for 2023 q1
SEC form 6
2023-06-05 16:07 ET
DermTech published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
DermTech published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
DermTech published news for 2023 q1
SEC form 6
2023-04-11 16:08 ET
DermTech published news for 2023 q1
SEC form 6
2023-03-31 16:11 ET
DermTech published news for 2022 q4
SEC form 6
2023-03-13 16:37 ET
DermTech published news for 2022 q4
SEC form 6
2023-03-09 20:17 ET
DermTech published news for 2022 q4
SEC form 6
2023-03-09 20:06 ET
DermTech published news for 2022 q4
SEC form 10
2023-03-02 16:36 ET
DermTech published news for 2022 q4
SEC form 6
2023-03-02 16:08 ET
DermTech published news for 2022 q4
SEC form 8
2023-03-02 00:00 ET
DermTech reported for 2022 q4
SEC form 10
2023-03-02 00:00 ET
DermTech reported for 2022 q4
SEC form 6
2023-01-06 20:03 ET
DermTech published news for 2022 q4
SEC form 6
2022-12-14 20:14 ET
DermTech published news for 2022 q3
SEC form 6
2022-12-14 20:00 ET
DermTech published news for 2022 q3
SEC form 6
2022-11-15 16:10 ET
DermTech published news for 2022 q3
SEC form 6
2022-11-14 16:25 ET
DermTech published news for 2022 q3
SEC form 10
2022-11-03 16:46 ET
DermTech published news for 2022 q3
SEC form 6
2022-11-03 16:06 ET
DermTech published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
DermTech reported for 2022 q3
SEC form 10
2022-08-08 16:22 ET
DermTech published news for 2022 q2
SEC form 6
2022-08-08 16:04 ET
DermTech published news for 2022 q2
SEC form 8
2022-08-08 00:00 ET
DermTech reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
DermTech reported for 2022 q2
SEC form 6
2022-07-20 20:11 ET
DermTech published news for 2022 q2
SEC form 6
2022-07-20 20:08 ET
DermTech published news for 2022 q2
SEC form 6
2022-07-18 17:27 ET
DermTech published news for 2022 q2
SEC form 6
2022-05-31 16:05 ET
DermTech published news for 2022 q1
SEC form 10
2022-05-03 17:05 ET
DermTech published news for 2022 q1
SEC form 6
2022-05-03 16:05 ET
DermTech published news for 2022 q1
SEC form 10
2022-05-03 00:00 ET
DermTech reported for 2022 q1
SEC form 8
2022-05-03 00:00 ET
DermTech reported for 2022 q1
SEC form 6
2022-04-28 16:06 ET
DermTech published news for 2022 q1
SEC form 6
2022-04-14 16:05 ET
DermTech published news for 2022 q1
SEC form 10
2022-03-10 16:06 ET
DermTech published news for 2021 q4
SEC form 10
2022-03-10 00:00 ET
DermTech published news for 2021 q4
SEC form 6
2022-03-01 18:04 ET
DermTech published news for 2021 q4
SEC form 6
2022-03-01 16:05 ET
DermTech published news for 2021 q4
SEC form 8
2022-03-01 00:00 ET
DermTech published news for 2021 q4
SEC form 10
2021-11-09 16:40 ET
DermTech published news for 2021 q3
SEC form 6
2021-11-09 16:05 ET
DermTech published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
DermTech published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
DermTech published news for 2021 q3
SEC form 6
2021-10-07 20:24 ET
DermTech published news for 2021 q3
SEC form 6
2021-10-06 16:01 ET
DermTech published news for 2021 q3
SEC form 10
2021-08-04 17:06 ET
DermTech published news for 2021 q2
SEC form 6
2021-08-04 16:05 ET
DermTech published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
DermTech published news for 2021 q2
SEC form 6
2021-07-07 21:20 ET
DermTech published news for 2021 q2
SEC form 6
2021-07-07 17:01 ET
DermTech published news for 2021 q2
SEC form 6
2021-07-02 17:00 ET
DermTech published news for 2021 q2
SEC form 6
2021-05-27 16:31 ET
DermTech published news for 2021 q1
SEC form 10
2021-05-13 17:01 ET
DermTech published news for 2021 q1
SEC form 6
2021-05-13 16:05 ET
DermTech published news for 2021 q1
SEC form 10
2021-05-13 00:00 ET
DermTech published news for 2021 q1
SEC form 6
2021-04-16 16:10 ET
DermTech published news for 2021 q1
SEC form 6
2021-04-01 16:32 ET
DermTech published news for 2021 q1
SEC form 10
2021-03-05 17:01 ET
DermTech published news for 2020 q4
SEC form 6
2021-03-04 16:05 ET
DermTech published news for 2020 q4
SEC form 6
2021-01-07 06:15 ET
DermTech published news for 2020 q4
SEC form 6
2021-01-06 16:10 ET
DermTech published news for 2020 q4
SEC form 6
2021-01-05 16:35 ET
DermTech published news for 2020 q4
SEC form 6
2020-12-11 06:03 ET
DermTech published news for 2020 q3
SEC form 10
2020-11-10 16:32 ET
DermTech published news for 2020 q3
SEC form 6
2020-11-10 16:08 ET
DermTech published news for 2020 q3